Saliba E, Laugier J
Unité INSERM 316-unité pédiatrique de soins intensifs, CHU Clocheville, Tours, France.
Pediatrie. 1993;48(12):864-71.
Over the last decade there has been major progresses in the pathophysiology, diagnosis and treatment of the respiratory distress syndrome of the neonate (RDS). This has resulted in a better understanding of the function of the surfactant system of the lung, whose deficiency almost invariably causes the onset of RDS. In the last eight years, great efforts have been devoted to the development and validation of surfactant replacement therapy for RDS. Natural, semi-synthetic and synthetic surfactants have been developed and tested in a variety of clinical settings, and many clinical trials have shown the validity of such therapeutical options. Surfactant replacement therapy is now routinely used in neonatal intensive care units. However, many questions need to be answered concerning the first choice between the different surfactant preparations and their administration modalities.
在过去十年中，新生儿呼吸窘迫综合征（RDS）的病理生理学、诊断和治疗取得了重大进展。这使得人们对肺表面活性物质系统的功能有了更好的理解，该系统的缺乏几乎总是导致RDS的发病。在过去八年中，人们致力于开发和验证用于RDS的表面活性物质替代疗法。天然、半合成和合成表面活性物质已在各种临床环境中得到开发和测试，许多临床试验表明了这些治疗选择的有效性。表面活性物质替代疗法现在在新生儿重症监护病房中常规使用。然而，关于不同表面活性物质制剂及其给药方式的首选，仍有许多问题需要解答。
